Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770347 | 1.00 | MAOA (0.40) | MAOAMAOBMAPKAPK2DRD1 | |
| SCHEMBL28660534 | 0.89 | MAOA (0.40) | MAOAMAOBMAPKAPK2DRD1 | |
| SCHEMBL28904464 | 0.82 | NPSR1 (0.32) | MAOAMAOB | |
| SCHEMBL6698583 | 0.77 | MAOA (0.52) | MAOAMAOBMAPKAPK2 | |
| SCHEMBL6599502 | 0.77 | MAOA (0.42) | MAOAMAOBMAPKAPK2 | |
| SCHEMBL6599506 | 0.72 | MAOA (0.43) | MAOAMAOBMAPKAPK2DRD1 | |
| SCHEMBL30168142 | 0.71 | MAOA (0.46) | MAOAMAOBMAPKAPK2DRD1 | |
| SCHEMBL2658102 | 0.71 | MAOA (0.46) | MAOAMAOBMAPKAPK2DRD1 | |
| SCHEMBL31673358 | 0.69 | MAOA (0.50) | MAOAMAOBDRD1 | |
| SCHEMBL115187 | 0.69 | MAOA (0.50) | MAOAMAOBMAPKAPK2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025082353-A1 | POLYMORPHIC FORMS OF THE COMPOUNDS TARGETING MUTANT OF P53 AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20240376075-A1 | POLYMORPHIC FORMS OF AURORA A SELECTIVE INHIBITORS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-118666870-A | Pyrimidopyridine compounds, pharmaceutical compositions and uses thereof | 华南理工大学 | 2024-09-20 | — | — | CN | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024120471-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024041503-A1 | COMPOUNDS TARGETING Y220C MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| EP-2804855-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | Tianjin Binjiang Pharma, Inc. (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2013107283-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2013-07-25 | — | — | WO | disclosed |
| WO-2012142956-A1 | PREPARATION METHOD OF TRIFLUOROSTYRENE COMPOUND | 中国科学院上海有机化学研究所 (CN) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012102985-A1 | ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, CDK1, MAP3K1 | MAOA 3342/4885MAOB 2698/4885MAPKAPK2 86/4885 |
| US-20240376075-A1 | POLYMORPHIC FORMS OF AURORA A SELECTIVE INHIBITORS AND USES THEREOF | AURKA, AURKC, AURKB | MAOA 1827/4885MAOB 2526/4885MAPKAPK2 1311/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | MAOA 4207/4885MAOB 4327/4885MAPKAPK2 716/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | MAOA 729/4885MAOB 293/4885MAPKAPK2 1491/4885 |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | MAVS, CCR5, NFATC1 | MAOA 2448/4885MAOB 1822/4885MAPKAPK2 3788/4885 |
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | TYK2, JAK2, JAK1 | MAOA 1895/4885MAOB 1497/4885MAPKAPK2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.